BRNIBlanchette Rockefeller Neurosciences Institute (Morgantown, WV)
BRNIBlue Ridge Numerics, Inc. (Charlottesville, VA)
BRNIBlue Ridge Numerics, Incorporated
References in periodicals archive ?
Shana Phares, CEO at BRNI adds, "We are so proud of Helen and the work she has led at BRNI.
BRNI was founded in 1999 in memory of Blanchette Ferry Hooker Rockefeller, an Alzheimer's patient and mother of U.
There are, of course, some exciting new directions in developing drugs to treat AD, including those being pursued at BRNI (see this issue).
Drug equivalents of Bryostatin, but with different chemical structures have been developed at BRNI.
These data from BRNI, together with the collective clinical experience with AD, the characteristic pathologic changes, the genetic mutation linked to familial AD, and curative effects of non-toxic PKC [epsilon] activators leads us to a new synthesis for both the early causes and the consequent pathologic changes of the disease.
PCPs will use this more than any other group of practitioners and BRNI will be providing extensive education prior to the registry being fully implemented.
The first-ever West Virginia Alzheimer's Disease Registry to collect data on patients and the disease in order to better inform state allocation of resources and to help guide BRNI research.
Based upon a number of BRNI pre-clinical and autopsy-validated human studies that have implicated PKCe deficits as a potential cause of Alzheimer's disease, the Company is approaching the treatment of the disease through the activation of PKCe.
Based on a number of BRNI pre-clinical and autopsy-validated human studies that have implicated PKC deficits as a cause of Alzheimer's disease, patient IV-18 was treated with the potent PKC epsilon activator, Bryostatin.
Dan Alkon, of BRNI, has shown that PKCe, when stimulated, initiates a cascade of enzymatic events, ultimately improves synaptic function, induces formation of new synapses and inhibits cell death.
Several variations of this complex product have been achieved in recent years in various academic chemistry laboratories, including bryostatin derivatives being developed through an exclusive license with Stanford University and the existing license agreement with BRNI.
Also, as part of its license from BRNI, the Company, under its BRNI license, has the rights to pursue treatments for a number of orphan diseases, including Fragile X Syndrome.